| Filed On | Filing |
|---|---|
| 09 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
1. Purpose. The Board of Directors of Vistagen Therapeutics, Inc. (the “Board”), a Nevada corporation (“Vistagen” or the “Company”), recognizes that a potential involuntary termination of employment of Vistagen’s senior management, inclu... |
| 25 Sep 2026 |
8-K: Regulation FD Disclosure
1 Nasdaq: VTGN Corporate Presentation Harnessing the therapeutic power and potential of brain regulation with nose-to-brain neurocircuitry September 2026 |
| 24 Sep 2026 |
8-K: Other Events
Exploratory research results presented at Psych Congress 2026 in New Orleans |
| 22 Sep 2026 |
8-K: Other Events
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder |
| 11 Sep 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On September 10, 2026, Vistagen Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). At the 2026 Annual Meeting, as set forth below, the Company’s stockholders: (i) elected each of ... |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | 10-Q |
| 14 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 06 Aug 2026 | 8-K: Regulation FD Disclosure; Other Events |
| 05 Aug 2026 | 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule |
| 31 Jul 2026 | DEFA14A |
| 31 Jul 2026 |
Proxy statement: annual meeting on September 10, 2026
CEO pay $1.2M, down 51% · say-on-pay vote |
| 31 Jul 2026 |
Form 4: Williamson Douglas J, Director
Granted 40,826 Stock Options (Right to Buy) |
| 31 Jul 2026 |
Form 3: Williamson Douglas J, Director
No securities owned |
| 31 Jul 2026 | 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure |
| 02 Jul 2026 |
Form 4: Adler Reid G., Chief Legal Officer
Received 36,818 shares as a grant or award ($7.07K) |
| 02 Jul 2026 |
Form 4: Tressler Nick B., Chief Financial Officer
Received 11,712 shares as a grant or award ($2.25K) |
| 02 Jul 2026 |
Form 4: Singh Shawn, Director
Received 36,818 shares as a grant or award ($7.07K) |
Loading...
